Leveraging Serologic Testing to Identify Children at Risk For Post-Acute Sequelae of SARS-CoV-2 Infection: An Electronic Health Record–Based Cohort Study from the RECOVER Program

Asuncion Mejias; Julia Schuchard; Suchitra Rao; Tellen D. Bennett; Ravi Jhaveri; Deepika Thacker; L. Charles Bailey; Dimitri A. Christakis; Nathan M. Pajor; Hanieh Razzaghi; Christopher B. Forrest; Grace M. Lee

doi:10.1016/j.jpeds.2023.02.005

Leveraging Serologic Testing to Identify Children at Risk For Post-Acute Sequelae of SARS-CoV-2 Infection: An Electronic Health Record–Based Cohort Study from the RECOVER Program

Asuncion Mejias^*, Julia Schuchard, Suchitra Rao, Tellen D. Bennett, Ravi Jhaveri, Deepika Thacker, L. Charles Bailey, Dimitri A. Christakis, Nathan M. Pajor, Hanieh Razzaghi, Christopher B. Forrest, Grace M. Lee

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Using an electronic health record–based algorithm, we identified children with Coronavirus disease 2019 (COVID-19) based exclusively on serologic testing between March 2020 and April 2022. Compared with the 131 537 polymerase chain reaction–positive children, the 2714 serology-positive children were more likely to be inpatients (24% vs 2%), to have a chronic condition (37% vs 24%), and to have a diagnosis of multisystem inflammatory syndrome in children (23% vs <1%). Identification of children who could have been asymptomatic or paucisymptomatic and not tested is critical to define the burden of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 infection in children.

Original language	English (US)
Article number	113358
Journal	journal of pediatrics
Volume	257
DOIs	https://doi.org/10.1016/j.jpeds.2023.02.005
State	Published - Jun 2023

Funding

This research was funded by National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the RECOVER Program, the NIH, or other funders. This research was funded by National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the RECOVER Program, the NIH, or other funders.A.M. reports funding from Janssen and Merck for research support and from Janssen, Merck, and Sanofi-Pasteur for advisory board participation. S.R. reports prior grant support from GSK and BioFire and serves as a consultant for Sequiris. R.J. serves as a consultant for AstraZeneca, Seqirus, and Dynavax and receives an editorial stipend from Elsevier. The other authors declare no conflicts of interest.

Keywords

COVID-19 serology
PEDSnet
anti-N antibodies
anti-S antibodies
chronic COVID-19 syndrome
late sequelae of COVID-19
long COVID
long-haul COVID-19
long-term COVID-19
post-acute COVID-19
post-acute sequelae of COVID-19
post-acute sequelae of SARS-CoV-2 infection
post–COVID-19 syndrome

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jpeds.2023.02.005

Cite this

Mejias, A., Schuchard, J., Rao, S., Bennett, T. D., Jhaveri, R., Thacker, D., Bailey, L. C., Christakis, D. A., Pajor, N. M., Razzaghi, H., Forrest, C. B., & Lee, G. M. (2023). Leveraging Serologic Testing to Identify Children at Risk For Post-Acute Sequelae of SARS-CoV-2 Infection: An Electronic Health Record–Based Cohort Study from the RECOVER Program. journal of pediatrics, 257, Article 113358. https://doi.org/10.1016/j.jpeds.2023.02.005

@article{87c7344bd06e4ac6a0c6e38da4323c9e,

title = "Leveraging Serologic Testing to Identify Children at Risk For Post-Acute Sequelae of SARS-CoV-2 Infection: An Electronic Health Record–Based Cohort Study from the RECOVER Program",

abstract = "Using an electronic health record–based algorithm, we identified children with Coronavirus disease 2019 (COVID-19) based exclusively on serologic testing between March 2020 and April 2022. Compared with the 131 537 polymerase chain reaction–positive children, the 2714 serology-positive children were more likely to be inpatients (24% vs 2%), to have a chronic condition (37% vs 24%), and to have a diagnosis of multisystem inflammatory syndrome in children (23% vs <1%). Identification of children who could have been asymptomatic or paucisymptomatic and not tested is critical to define the burden of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 infection in children.",

keywords = "COVID-19 serology, PEDSnet, anti-N antibodies, anti-S antibodies, chronic COVID-19 syndrome, late sequelae of COVID-19, long COVID, long-haul COVID-19, long-term COVID-19, post-acute COVID-19, post-acute sequelae of COVID-19, post-acute sequelae of SARS-CoV-2 infection, post–COVID-19 syndrome",

author = "Asuncion Mejias and Julia Schuchard and Suchitra Rao and Bennett, {Tellen D.} and Ravi Jhaveri and Deepika Thacker and Bailey, {L. Charles} and Christakis, {Dimitri A.} and Pajor, {Nathan M.} and Hanieh Razzaghi and Forrest, {Christopher B.} and Lee, {Grace M.}",

note = "Funding Information: This research was funded by National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the RECOVER Program, the NIH, or other funders. Funding Information: This research was funded by National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the RECOVER Program, the NIH, or other funders.A.M. reports funding from Janssen and Merck for research support and from Janssen, Merck, and Sanofi-Pasteur for advisory board participation. S.R. reports prior grant support from GSK and BioFire and serves as a consultant for Sequiris. R.J. serves as a consultant for AstraZeneca, Seqirus, and Dynavax and receives an editorial stipend from Elsevier. The other authors declare no conflicts of interest. Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = jun,

doi = "10.1016/j.jpeds.2023.02.005",

language = "English (US)",

volume = "257",

journal = "journal of pediatrics",

issn = "0022-3476",

publisher = "Elsevier Inc.",

}

Mejias, A, Schuchard, J, Rao, S, Bennett, TD, Jhaveri, R, Thacker, D, Bailey, LC, Christakis, DA, Pajor, NM, Razzaghi, H, Forrest, CB & Lee, GM 2023, 'Leveraging Serologic Testing to Identify Children at Risk For Post-Acute Sequelae of SARS-CoV-2 Infection: An Electronic Health Record–Based Cohort Study from the RECOVER Program', journal of pediatrics, vol. 257, 113358. https://doi.org/10.1016/j.jpeds.2023.02.005

TY - JOUR

T1 - Leveraging Serologic Testing to Identify Children at Risk For Post-Acute Sequelae of SARS-CoV-2 Infection

T2 - An Electronic Health Record–Based Cohort Study from the RECOVER Program

AU - Mejias, Asuncion

AU - Schuchard, Julia

AU - Rao, Suchitra

AU - Bennett, Tellen D.

AU - Jhaveri, Ravi

AU - Thacker, Deepika

AU - Bailey, L. Charles

AU - Christakis, Dimitri A.

AU - Pajor, Nathan M.

AU - Razzaghi, Hanieh

AU - Forrest, Christopher B.

AU - Lee, Grace M.

N1 - Funding Information: This research was funded by National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the RECOVER Program, the NIH, or other funders. Funding Information: This research was funded by National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the RECOVER Program, the NIH, or other funders.A.M. reports funding from Janssen and Merck for research support and from Janssen, Merck, and Sanofi-Pasteur for advisory board participation. S.R. reports prior grant support from GSK and BioFire and serves as a consultant for Sequiris. R.J. serves as a consultant for AstraZeneca, Seqirus, and Dynavax and receives an editorial stipend from Elsevier. The other authors declare no conflicts of interest. Publisher Copyright: © 2023 Elsevier Inc.

PY - 2023/6

Y1 - 2023/6

N2 - Using an electronic health record–based algorithm, we identified children with Coronavirus disease 2019 (COVID-19) based exclusively on serologic testing between March 2020 and April 2022. Compared with the 131 537 polymerase chain reaction–positive children, the 2714 serology-positive children were more likely to be inpatients (24% vs 2%), to have a chronic condition (37% vs 24%), and to have a diagnosis of multisystem inflammatory syndrome in children (23% vs <1%). Identification of children who could have been asymptomatic or paucisymptomatic and not tested is critical to define the burden of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 infection in children.

AB - Using an electronic health record–based algorithm, we identified children with Coronavirus disease 2019 (COVID-19) based exclusively on serologic testing between March 2020 and April 2022. Compared with the 131 537 polymerase chain reaction–positive children, the 2714 serology-positive children were more likely to be inpatients (24% vs 2%), to have a chronic condition (37% vs 24%), and to have a diagnosis of multisystem inflammatory syndrome in children (23% vs <1%). Identification of children who could have been asymptomatic or paucisymptomatic and not tested is critical to define the burden of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 infection in children.

KW - COVID-19 serology

KW - PEDSnet

KW - anti-N antibodies

KW - anti-S antibodies

KW - chronic COVID-19 syndrome

KW - late sequelae of COVID-19

KW - long COVID

KW - long-haul COVID-19

KW - long-term COVID-19

KW - post-acute COVID-19

KW - post-acute sequelae of COVID-19

KW - post-acute sequelae of SARS-CoV-2 infection

KW - post–COVID-19 syndrome

UR - http://www.scopus.com/inward/record.url?scp=85151409989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151409989&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2023.02.005

DO - 10.1016/j.jpeds.2023.02.005

M3 - Article

C2 - 36822507

AN - SCOPUS:85151409989

SN - 0022-3476

VL - 257

JO - journal of pediatrics

JF - journal of pediatrics

M1 - 113358

ER -

Leveraging Serologic Testing to Identify Children at Risk For Post-Acute Sequelae of SARS-CoV-2 Infection: An Electronic Health Record–Based Cohort Study from the RECOVER Program

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this